# An induced pluripotent stem cell-based chemical genetic approach for studying spinal muscular atrophy

**Authors:** Richard M. Giadone, Kristina M. Holton, Xiaoyu Hu, Ted Natoli, Sabrina Ghosh, Stanley P. Gill, Nicholas Lyons, Aravind Subramanian, Lee L. Rubin

PMC · DOI: 10.3389/fnins.2025.1695359 · Frontiers in Neuroscience · 2026-02-04

## TL;DR

This paper introduces a new method using stem cells and chemical screening to study spinal muscular atrophy and identify potential treatments.

## Contribution

The novel contribution is the development of CMAPneuro, a platform for studying SMA using patient-derived neurons and chemical-genetic screening.

## Key findings

- Generated 4,559 transcriptional profiles from SMA neurons exposed to 360 compounds.
- Identified stimuli that modulate gene expression differences in SMA neurons.
- Created a queryable database for exploring CNS disease-related perturbagens and their effects.

## Abstract

Spinal muscular atrophy (SMA) is a genetic disease characterized by degeneration of spinal cord motor neurons and neuromuscular junctions. Despite recent developments in therapies for SMA, treatment efficacy largely relies on the administration of drugs early in disease progression and is impacted by underlying patient genetics. Drug discovery for other diseases of the central nervous system (CNS) has also been hindered by heterogeneity in patient genetics and clinical presentations, as well as the need for early intervention.

To address these hurdles, we utilized a chemical-genetic-based screening approach to adapt the Connectivity Map (CMAP)/L1000 platform to study SMA. To do this, we differentiated moderate and severe SMA patient-specific induced pluripotent stem cells into neuronal cells utilizing a forward programming differentiation protocol, exposed each to 360 neuroactive or CNS disease-related compounds, and interrogated resulting changes in expression of >400 neural genes in a platform we term CMAPneuro.

In doing so, we generated 4,559 transcriptional profiles identifying stimuli that modulate gene expression differences across SMA neurons. Finally, we make these data queryable, allowing the research community to (1) identify CNS disease-related perturbagens that mimic or reverse differentially expressed genes, or (2) explore the transcriptional response of a given perturbation in diverse SMA neuronal cells.

Taken together, CMAPneuro represents a novel tool to identify candidate stimuli for follow-up investigation into the biology of SMA and related disorders.

## Linked entities

- **Diseases:** spinal muscular atrophy (MONDO:0001516)

## Full-text entities

- **Genes:** SMN2 (survival of motor neuron 2, centromeric) [NCBI Gene 6607] {aka BCD541, C-BCD541, GEMIN1, SMNC, TDRD16B}, ROCK1 (Rho associated coiled-coil containing protein kinase 1) [NCBI Gene 6093] {aka P160ROCK, ROCK-I}, GRIN1 (glutamate ionotropic receptor NMDA type subunit 1) [NCBI Gene 2902] {aka DEE101, GluN1, MRD8, NDHMSD, NDHMSR, NMD-R1}, BMI1 (BMI1 proto-oncogene, polycomb ring finger) [NCBI Gene 648] {aka FLVI2/BMI1, PCGF4, RNF51, flvi-2/bmi-1}, MRAP (melanocortin 2 receptor accessory protein) [NCBI Gene 56246] {aka B27, C21orf61, FALP, GCCD2, MRAP1}, CNTF (ciliary neurotrophic factor) [NCBI Gene 1270] {aka HCNTF}, SNAP25 (synaptosome associated protein 25) [NCBI Gene 6616] {aka CMS18, DEE117, RIC-4, RIC4, SEC9, SNAP}, SYN1 (synapsin I) [NCBI Gene 6853] {aka EPILX, EPILX1, MRX50, SYN1a, SYN1b, SYNI}, EVL (Enah/Vasp-like) [NCBI Gene 51466] {aka RNB6}, Smn1 (survival motor neuron 1) [NCBI Gene 20595] {aka Gemin1, Smn}, BLNK (B cell linker) [NCBI Gene 29760] {aka AGM4, BASH, BLNK-S, LY57, SLP-65, SLP65}, TUBA1A (tubulin alpha 1a) [NCBI Gene 7846] {aka B-ALPHA-1, LIS3, TUBA3}, BDNF (brain derived neurotrophic factor) [NCBI Gene 627] {aka ANON2, BULN2}, GRIA1 (glutamate ionotropic receptor AMPA type subunit 1) [NCBI Gene 2890] {aka GLUH1, GLUR1, GLURA, GluA1, HBGR1, MRD67}, POU5F1 (POU class 5 homeobox 1) [NCBI Gene 5460] {aka OCT3, OCT4, OCT4Borf1, OTF-3, OTF3, OTF4}, NEUROG2 (neurogenin 2) [NCBI Gene 63973] {aka Atoh4, Math4A, NGN2, bHLHa8, ngn-2}, SENP5 (SUMO specific peptidase 5) [NCBI Gene 205564], GDNF (glial cell derived neurotrophic factor) [NCBI Gene 2668] {aka ATF, ATF1, ATF2, HFB1-GDNF, HSCR3}, SMN1 (survival of motor neuron 1, telomeric) [NCBI Gene 6606] {aka BCD541, GEMIN1, SMA, SMA1, SMA2, SMA3}, MAPT (microtubule associated protein tau) [NCBI Gene 4137] {aka DDPAC, FTD1, FTDP-17, MAPTL, MSTD, MTBT1}, CDH3 (cadherin 3) [NCBI Gene 1001] {aka CDHP, HJMD, PCAD}, CACNA1C (calcium voltage-gated channel subunit alpha1 C) [NCBI Gene 775] {aka CACH2, CACN2, CACNA1C-IT2, CACNL1A1, CCHL1A1, CaV1.2}, FN1 (fibronectin 1) [NCBI Gene 2335] {aka CIG, ED-B, FINC, FN, FNZ, GFND}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, STMN2 (stathmin 2) [NCBI Gene 11075] {aka SCG10, SCGN10}, THAS (thoracoabdominal syndrome) [NCBI Gene 7055] {aka TAS}, HDAC9 (histone deacetylase 9) [NCBI Gene 9734] {aka HD7, HD7b, HD9, HDAC, HDAC7B, HDAC9B}, VAMP2 (vesicle associated membrane protein 2) [NCBI Gene 6844] {aka NEDHAHM, SYB2, VAMP-2}, NANOG (Nanog homeobox) [NCBI Gene 79923], SYT1 (synaptotagmin 1) [NCBI Gene 6857] {aka BAGOS, P65, SVP65, SYT}, KCNQ2 (potassium voltage-gated channel subfamily Q member 2) [NCBI Gene 3785] {aka BFNC, DEE7, EBN, EBN1, ENB1, HNSPC}, BRD2 (bromodomain containing 2) [NCBI Gene 6046] {aka BRD2-IT1, D6S113E, FSH, FSHRG1, FSRG1, NAT}, SLC17A6 (solute carrier family 17 member 6) [NCBI Gene 57084] {aka DNPI, VGLUT2}, TBX3 (T-box transcription factor 3) [NCBI Gene 6926] {aka TBX3-ISO, UMS, XHL}, CAMK2A (calcium/calmodulin dependent protein kinase II alpha) [NCBI Gene 815] {aka CAMKA, CaMKIINalpha, CaMKIIalpha, MRD53, MRT63}, DLG4 (discs large MAGUK scaffold protein 4) [NCBI Gene 1742] {aka MRD62, PSD95, SAP-90, SAP90}, CDK4 (cyclin dependent kinase 4) [NCBI Gene 1019] {aka CMM3, MCPH31, PSK-J3}, MAP2 (microtubule associated protein 2) [NCBI Gene 4133] {aka MAP-2, MAP2A, MAP2B, MAP2C}, RBFOX3 (RNA binding fox-1 homolog 3) [NCBI Gene 146713] {aka FOX-3, FOX3, HRNBP3, NEUN}
- **Diseases:** myelogenous leukemia (MESH:D007951), cervical cancer (MESH:D002583), Parkinson's Disease (MESH:D010300), degenerative motor neuron disease (MESH:D019636), diseases of the (MESH:D004194), muscle damage (MESH:D009133), prostate cancer (MESH:D011471), SMA (MESH:D009134), CNS diseases (MESH:D002493), schizophrenia (MESH:D012559), AD (MESH:D000544), cancer (MESH:D009369), 3 type 3 SMA (MESH:D014897), neurological disease (MESH:D020271), neurological disorders (MESH:D009461), genetic disease (MESH:D030342), Type 0/1 (MESH:C565390), deficiency of survival of motor neuron (SMN (MESH:D011475), protein (MESH:D011488), acute promyelocytic leukemia (MESH:D015473), breast cancer (MESH:D001943), diseases of the nervous system (MESH:D009422), Neuromuscular Disorders (MESH:D009468)
- **Chemicals:** doxycycline (MESH:D004318), nizatidine (MESH:D016567), thapsigargin (MESH:D019284), Triton X-100 (MESH:D017830), LDN-193189 (MESH:C554430), AMG-925 (MESH:C000589290), EDTA (MESH:D004492), F12 (MESH:C007782), N2 (MESH:D009584), tunicamycin (MESH:D014415), perzinfotel (MESH:C110623), MG132 (MESH:C072553), LY-2835219 (MESH:C000590451), taranabant (MESH:C521311), risdiplam (MESH:C000629884), glutamax (MESH:C054122), AZD-2858 (MESH:C583189), SDS (MESH:D012967), SKF-81297 (MESH:C067113), phenformin (MESH:D010629), puromycin (MESH:D011691), AA-29504 (-), BML-190 (MESH:C471852), disulfiram (MESH:D004221), Alvocidib (MESH:C077990), dapiprazole (MESH:C035289), XAV939 (MESH:C544261), itopride (MESH:C102254), paraformaldehyde (MESH:C003043), U (MESH:D014501), AMG-517 (MESH:C523409), CP-945598 (MESH:C535235), SB431542 (MESH:C459179), borate (MESH:D001881), dextrose (MESH:D005947), SB-269970 (MESH:C404922), piracetam (MESH:D010889), DMSO (MESH:D004121), PBS (MESH:D007854), poly-L-ornithine (MESH:C008973)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Lentivirus (genus) [taxon 11646], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** BD35427 — Homo sapiens (Human), Seizure disorder, Transformed cell line (CVCL_FS86), 293 T — Homo sapiens (Human), Transformed cell line (CVCL_0063), AMG-925 — Homo sapiens (Human), Lung adenocarcinoma, Cancer cell line (CVCL_U096)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12913379/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12913379/full.md

## References

43 references — full list in the complete paper: https://tomesphere.com/paper/PMC12913379/full.md

---
Source: https://tomesphere.com/paper/PMC12913379